Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Apple won the case, though was only awarded a nominal $250, which is the smallest amount it was possible for the court to order. In other words, yes Masimo did in infringe Apple’s patents, but there ...

The litigation in Delaware became more complex when Masimo launched its W1 consumer watch in January 2022. Later, it was shown to replicate the core design elements of the Apple Watch, including a ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Reports Q3 revenue $504.6M, consensus $502.67M. Michelle Brennan, Interim Chief Executive Officer of Masimo (MASI), said, “We are pleased ...

Piper Sandler raised the firm’s price target on Masimo (MASI) to $180 from $165 and keeps an Overweight rating on the shares. The firm ...

Masimo (NASDAQ:MASI) is set to give its latest ... remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures ...

--(BUSINESS WIRE)--Masimo Corporation (Nasdaq ... We are also progressing on our strategic review of the consumer business and are focused on delivering the best outcome for our shareholders.

A federal jury ruled Friday that Masimo smartwatches infringed Apple patents, but Apple isn’t getting a big payday. Bloomberg Law reports that the company was only seeking the statutory minimum ...

Masimo Corp (NASDAQ:MASI) is undergoing a strategic review process for its consumer business, which could lead to uncertainties regarding its future structure and financial impact. The company has ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.